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Loss of p16
INK4a–RB and ARF–p53 tumor suppressor
pathways, as well as activation of RAS–RAF signaling, is
seen in a majority of human melanomas. Although
heterozygous germline mutations of p16
INK4a are asso-
ciated with familial melanoma, most melanomas result
from somatic genetic events: often p16
INK4a loss and
N-RAS or B-RAF mutational activation, with a minority
possessing alternative genetic alterations such as activat-
ing mutations in K-RAS and/or p53 inactivation. To
generate a murine model of melanoma featuring some of
these somatic genetic events, we engineered a novel condi-
tional p16
INK4a-null allele and combined this allele with a
melanocyte-speciﬁc, inducible CRE recombinase strain, a
conditional p53-null allele and a loxP-stop-loxP activatable
oncogenic K-Ras allele. We found potent synergy between
melanocyte-speciﬁc activation of K-Ras and loss of p16
INK4a
and/or p53 in melanomagenesis. Mice harboring melanocyte-
speciﬁc activated K-Ras and loss of p16
INK4a and/or p53
developed invasive, unpigmented and nonmetastatic melano-
mas with short latency and high penetrance. In addition, the
capacity of these somatic genetic events to rapidly induce
melanomas in adult mice suggests that melanocytes remain
susceptible to transformation throughout adulthood.
Oncogene (2010) 29, 5809–5817; doi:10.1038/onc.2010.314;
published online 9 August 2010
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Introduction
Melanoma, the most lethal form of skin cancer, is
increasing in incidence and mortality in the United
States (Chin et al., 2006). Alterations of three genetic
pathways characterize the majority of melanomas:
activation of the RAS–RAF–extracellular signal-
regulated kinase (ERK) pathway, inactivation of the
p16
INK4a–CDK4–retinoblastoma (RB) pathway and
inactivation of the alternate open reading frame
(ARF)–murine double minute 2–p53 pathway. The
RAS–RAF–ERK pathway is a mitogen-activated kinase
cascade, which induces diverse transcriptional changes
associated with increased proliferation, survival,
motility and immune surveillance (Pearson et al., 2000;
Johansson et al., 2007; Petermann et al., 2007; Shields
et al., 2007). Per the Compilation of Somatic Mutations
in Cancer (COSMIC, see (Forbes et al., 2006)),
activating mutations of N-RAS occur in 21% of
melanomas, those of K-RAS in 2% and of B-RAF in
44%, and these lesions seem to be mutually exclusive,
consistent with an epistatic relationship. The presence of
activating B-RAF mutations in a high proportion of
dysplastic nevi indicates that aberrant activation of the
RAS–RAF pathway is not sufﬁcient for tumorigenesis
and that additional genetic lesions are required to effect
malignant transformation (Davies et al., 2002). Strong
RAS–RAF activation has been shown to induce p16
INK4a
expression and ‘oncogene-induced senescence’ in vitro
and in vivo (Serrano et al., 1997; Zhu et al., 1998;
Michaloglou et al., 2005), providing a tumor biological
basis for cooperative interactions between p16
INK4a
extinction and RAS–RAF activation.
The INK4/ARF (CDKN2a/b) locus at 9p21 encodes
three distinct tumor suppressor proteins—p15
INK4b,
p16
INK4a and ARF. A signiﬁcant body of human and
murine genetic data have determined that p16
INK4a and
ARF have an important role in melanoma suppression
(reviewed in (Kim and Sharpless, 2006)), whereas the role
of p15
INK4b in this disease is less clear. INK4a/ARF
deletion occurs in 50% of human melanomas, making it
the most common site of genomic loss in melanomas
(Curtin et al., 2005), with homozygous deletion being
relatively common (Grafstrom et al., 2005). ARF blocks
murine double minute 2-induced degradation of p53,
whereas p16
INK4a and p15
INK4b inhibit cyclin-dependent
kinases 4 and 6 , leading to RB-hypophosphorylation and
cell cycle arrest. Although ARF loss is the most common
lesion of the ARF–murine double minute 2–p53 pathway
in melanoma, mutational inactivation of p53 is observed
in 10–30% of melanomas (Albino et al., 1994; Sparrow
et al., 1995; Akslen et al., 1998; Zerp et al., 1999).
Several genetically engineered mouse models of
melanoma using constitutively active and inducible
transgenes and germline knockout alleles have studied
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loss. Mice engineered with a constitutive, melanocyte-
speciﬁc, mutant H-Ras transgenic allele on an Ink4a/
Arf-deﬁcient background (TyrRas Ink4a/Arf  / ) were
shown to develop melanoma with high penetrance and
short latency (Chin et al., 1997). Using a doxycycline-
inducible mutant H-Ras allele on an Ink4a/Arf-deﬁcient
background, it was determined that persistent activa-
tion of H-Ras is required for both melanoma initiation
and maintenance, thus establishing the concept of
tumor maintenance (Chin et al., 1999). Melanocyte-
speciﬁc expression of an activated N-Ras transgene in
an Ink4a/Arf-deﬁcient background can also generate
melanomas that can metastasize to the lymph nodes,
lung and liver (Ackermann et al., 2005). A role for
p53 in melanoma was substantiated in TyrRas trans-
genic mice that were mutant for p53, which develop
melanomas that retain strong p16
INK4a expression
(Bardeesy et al., 2001). It is noteworthy and of rele-
vance to this study that the TyrRas transgene on a
germline p16
INK4a-null background exhibited a weaker
melanoma phenotype when compared with the TyrRas
transgene on either a germline Arf or p53-null back-
ground (Bardeesy et al., 2001; Kannan et al., 2003). This
murine observation is curious in light of the prominent
role of p16
INK4a extinction in human melanomas, raising
the possibility of cross-species differences in the rate-
limiting role of this key RB pathway component
and/or of the fact that germline vs somatic inactivation
of p16
INK4a is a critical parameter of its impact on
melanocyte biology.
In aggregate, these genetic studies have clearly
established the cooperation of Ras activation and
Arf/p53 inactivation in melanomagenesis, but have
suggested a more modest role for p16
INK4a loss in driving
melanoma development in the mouse. This modest
impact of p16
INK4a loss seems to contrast with the
prominent role of p16
INK4a in human melanoma, as
reﬂected by the robust melanoma-prone condition in the
setting of germline or somatic p16
INK4a mutations that
spare Arf or p15
INK4b in many cases (FitzGerald et al.,
1996; Smith-Sorensen and Hovig, 1996; Walker et al.,
1998; Daniotti et al., 2004). It is important to note that a
few cases of ARF germline or somatic mutations that
spare p16
INK4a have been identiﬁed, suggesting that both
products of the INK4a/ARF locus have independent
tumor suppressor activity in melanoma (Rizos et al.,
2001; Hewitt et al., 2002). Several possible explanations
for the apparent cross-species differences have been
suggested, including differences in the anticancer
potency of p16
INK4a vs ARF between mouse and man
(Gil and Peters, 2006; Evan and d’Adda di Fagagna,
2009), bias derived from studies using transgene-driven
overexpression of activated Ras (Tuveson et al., 2004),
as well as epigenetic compensation in mice germline null
for p16
INK4a. With regard to the latter possibility,
germline p16
INK4a inactivation is associated with in-
creased, presumably compensatory, expression of other
negative regulators of the cell cycle, such as p15
INK4b and
p18
INK4c (Krimpenfort et al., 2007; Ramsey et al., 2007;
Wiedemeyer et al., 2008). Furthermore, somatic loss of
RB in vitro has been shown to transiently induce cell
cycle entry that is later compensated by other RB-family
proteins (Sage et al., 2003). Therefore, the apparent
differences between human and murine melanoma with
regard to tumor suppressor pathway inactivation could
reﬂect technical features of the experimental model
systems used or species differences between mouse
and man.
Conditional activated knock-in and tetracycline-in-
ducible alleles and conditional knockout alleles have
enabled the study of somatic mutations in adult mice.
The use of conditional strategies are particularly
relevant to melanoma research, in which epidemiologi-
cal studies have suggested that sun exposure during
childhood may be more effective at inducing melanoma
than sun exposure later in life (Bader et al., 1985;
Harrison et al., 1994; English et al., 2005). In accordance
with this view, Merlino and colleagues have shown
that ultraviolet B treatment of HGF/SF transgenic
mice effectively induces melanoma only in the neonatal
period (3.5 days), but not in adult mice (Noonan et al.,
2001). Similar results were noted in TyrRas Arf / 
mice, which also pointed to the p16
INK4a–RB pathway as
a key target of ultraviolet carcinogenic actions (Kannan
et al., 2003). These results could indicate that ultraviolet
B is less efﬁcient at causing oncogenic mutations in adult
mice, or that adult melanocytes are intrinsically more
resistant to the transforming effects of oncogenic
mutations. The latter model would be consistent with
the notion of a ‘developmental window’ at young age
during which melanocytes are more susceptible to
transformation by a given set of oncogenic events.
Building on this previous history of melanoma
modeling in mice, we used somatic and inducible alleles,
including a newly engineered ‘ﬂoxed’ p16
INK4a-speciﬁc
null allele, to study the effects of somatic, melanocyte-
speciﬁc loss of p16
INK4a and/or p53 combined with
somatic activation of an oncogenic K-Ras allele on
melanomagenesis in neonatal and adult mice.
Results
To determine the effect of somatic loss of p16
INK4a and/
or p53 and activation of oncogenic K-Ras, we used an
established 4-hydroxytamoxifen (4-OHT)-inducible mel-
anocyte-speciﬁc CRE allele (Tyr-CRE-ER
T2 (Bosenberg
et al., 2006)), together with conditional alleles such as
Lox-Stop-Lox-KRas
G12D (Johnson et al., 2001), a ﬂoxed
p53-null allele (p53
L (Jonkers et al., 2001) and a newly
generated ﬂoxed p16
INK4a-null allele (p16
L). In a subset
of mice, CRE recombination was conﬁrmed using a
b-galactosidase reporter allele that, on Cre-mediated
excision of a Lox-Stop-Lox cassette, expresses the
enzyme; it was observed that cells stain positively in
the b-galactosidase assay (Rosa26-LSL-b-galactosidase,
(Soriano, 1999)) (Supplementary Figure 1). The p16
L
allele was generated by inserting LoxP elements B3.5kb
50 to exon 1a and immediately 30 to the p16
INK4a exon 1a
(Supplementary Figure 2a, see also Supplementary
Methods). The 50 LoxP element was placed in a variable
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between 129SvJ and C57Bl/6 strains, and therefore not
likely to be a critical Ink4a/Arf regulator. Correct
targeting of the locus was conﬁrmed by Southern
blotting, PCR and sequencing (Supplementary Figure
2b and c). CRE expression in p16
L/L murine embryo
ﬁbroblasts and melanocytes demonstrated selective
p16
INK4a exon 1a excision, loss of p16
INK4a protein
expression (Supplementary Figure 3a and c) without
an alteration in Arf expression (Supplementary Figure
3b and c). In contrast to deletion of Arf or p53, excision
of p16
INK4a with or without concomitant K-Ras activa-
tion did not enhance melanocyte growth in vitro
(Supplementary Figure 3d).
Intercrosses produced the Tyr-CRE-ER
T2þKRas
LSL/þ
p16
L/Lp53
L/L experimental cohort (TKp16
L/Lp53
L/L), as
well as indicated control cohorts. TKp16
L/Lp53
L/L mice
and control littermates were topically treated as
neonates with 4-OHT to activate CRE and induce
recombination in melanocytes as previously described
(Bosenberg et al., 2006; see schematic in Supplementary
Figure 1). Within 14 weeks, all 4-OHT-treated TKp16
L/L
p53
L/L mice developed aggressive tumors and hence had
to be killed (Figure 1a, Table 1). Nonmelanoma tumors
were not observed in 4-OHT-treated TKp16
L/Lp53
L/L
mice (n¼15) (Table 1). In contrast, only 1 of 14 of
the 4-OHT-treated TKp16
þ/þp53
þ/þ mice developed
melanoma at 60 weeks post treatment (Table 1). PCR
conﬁrmed that all TKp16
L/Lp53
L/L tumors exhibited a
recombination of K-Ras, p16
INK4a and p53 alleles
(Figure 1b). Western analysis of TKp16
L/Lp53
L/L tumors
demonstrated an absence of expression of p16
INK4a and
p53, as well as of p21
CIP, a p53 target gene (Supple-
mentary Figure 4a). These data demonstrate potent
cooperation between activated K-Ras and combined
p16
INK4a and p53 loss in driving a highly penetrant and
aggressive melanoma condition.
To further dissect the contributions of each tumor
suppressor in melanoma development, we generated
and compared TKp16
L/L and TKp53
L/L cohorts. These
Figure 1 Somatic K-Ras activation coupled with p16
INK4a and/or p53 inactivation induces melanoma. (a) Kaplan–Meier analysis of
melanoma-free survival of 4-OHT-treated TK (n¼14), TKp16
L/Lp53
L/L (n¼15), TKp16
L/L (n¼11) and TKp53
L/L (n¼11) mice. Pairwise
statistical comparisons: TK vs TKp16
L/L (Po0.001), TK vs TKp53
L/L (Po0.001), TKp16
L/Lp53
L/L vs TKp16
L/L (Po0.001), TKp16
L/Lp53
L/L
vs TKp53
L/L (Po0.001) and TKp16
L/L vs TKp53
L/L (P¼NS). (b) PCR for the recombined alleles: K-Ras
LSLG12D, p16
L/L, p53
L/L in ears and
tumors from 4-OHT-treated or untreated TKp16
L/Lp53
L/L mice. (c) Representative tumors from each cohort are shown. Tumors from
mice of all genotypes exhibited a spindle-like morphology by hematoxylin and eosin staining and were stained for tyrosinase-related
protein 1, conﬁrming melanocytic origin. Original magniﬁcation:  100.
Table 1 Summary of tumor features by genotype
Genotype Tumors/treated
mice (%)
Median tumor
latency
Metastasis
TK 1/14 (7) 452 weeks None detected
a
Tp16
L/Lp53
L/L 1/19 (5) 452 weeks None detected
TKp16
L/L 8/11 (73) 24 weeks None detected
TKp53
L/L 5/11 (45) 31 weeks None detected
TKp16
L/þp53
L/þ 3/7 (43) 452 weeks None detected
TKp16
L/Lp53
L/L 15/15 (100) 9 weeks None detected
aOne lung tumor was noted in a 72-week-old animal of unclear
histogenesis.
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Oncogeneanimals were treated neonatally by topical 4-OHT and
followed up for tumor development, as outlined in
Supplementary Figure 1. Somatic, melanocyte-speciﬁc
loss of either p16
INK4a or p53 alone in this system led to
melanoma formation (Figure 1a) with signiﬁcantly
longer tumor latencies than seen in the TKp16
L/Lp53
L/L
cohort but, notably, shorter than the latencies of the
TKp16
þ/þp53
þ/þ mice. Unexpectedly, the 4-OHT-
treated TKp16
L/L and TKp53
L/L animals showed compar-
able median latencies of 24 and 31 weeks, respectively.
The 4-OHT-treated compound heterozygous mice
TKp16
L/þ and TKp53
L/þ showed accelerated tumorigen-
esis compared with 4-OHT-treated TK mice (Supple-
mentary Figure 4b and Table 1). As expected, mice with
somatic inactivation of p16
INK4a and p53 without
concomitant Ras activation (Tp16
L/Lp53
L/L) were only
weakly tumor prone (1 of 19 mice, Table 1).
At the histopathological level, tumors from the four
cohorts (TK, TKp16
L/L, TKp53
L/L and TKp16
L/Lp53
L/L)
exhibited a spindle-like morphology with scant pigmen-
tation and positive staining for TRP1 (Figure 1c,
Supplementary Figure 5). These ‘amelanotic’ melano-
mas are similar to those reported by Chin et al.(1997) in
the H-Ras-driven TyrRas Ink4a/Arf /  model, but
different from the heavily pigmented tumors noted in
N-Ras transgenic, Ink4a/Arf-deﬁcient mice (Ackermann
et al., 2005) and the conditional B-Raf and Pten mice
(Dankort et al., 2009). In contrast to the TyrRas Ink4a/
Arf /  model, in which tumors are limited to ears,
trunk, tail and uvea, tumors in the conditionally
activatable model occurred on the ﬂank, ear and tail,
and uveal tumors were not observed. An increased
tumor multiplicity was noted in 4-OHT-treated TKp16
L/L
p53
L/L mice compared with treated TK, TKp16
L/L or
TKp53
L/L animals; however, there were signiﬁcantly
more tumors from treated TKp16
L/Lp53
L/L mice when
compared with TK, TKp16
L/L or TKp53
L/L animals,
suggesting the increase in multiplicity could be due to an
increase in the overall number of tumors (Supplemen-
tary Figure 4c). These data suggest that p16
INK4a and p53
exert important and nonredundant antimelanoma roles
in the context of melanocyte-speciﬁc Ras activation, a
ﬁnding that may reﬂect the prominent involvement of
the Ink4a/Arf locus that dually encodes components of
the RB and p53 pathway (Sherr, 2001).
Mice from all cohorts (TK, TKp16
L/L, TKp53
L/L and
TKp16
L/Lp53
L/L) developed melanocytic proliferation in
the skin before tumor formation. Paws and tails of
treated mice from all cohorts developed pigmented
macules that were not present in wild-type or 4-OHT-
untreated littermates (Supplementary Figure 6a and b).
Wild-type and 4-OHT-untreated animals had little
melanin production in sections of the ear when
compared with treated mice from other cohorts. The
most pronounced effects were observed in skin from
4-OHT-treated-TKp16
L/Lp53
L/L mice (Supplementary
Figure 6c). These ﬁndings suggest that K-Ras activation
alone is sufﬁcient to produce a modest increase in
melanocytic proliferation, and that this excess, non-
malignant proliferation is partially restrained by the
combined activities of p16
INK4a and p53.
To determine the role of the INK4–cyclin-dependent
kinase 4 (Cdk4)–Rb pathway in melanocyte transforma-
tion in vivo, lysates of primary tumors were analyzed.
In tumors from 4-OHT-treated mice of informative
genotypes (TKp53
L/L, TKp16
L/þp53
L/þand TKp16
L/þ
p53
L/L), the majority (8 of 11) of tumors demonstrated
absent p16
INK4a expression (Figure 2a and b). Recently,
expression of p15
INK4b has been shown to have a ‘back-
up’ tumor suppressor role in p16
INK4a germline-deﬁcient
animals (Krimpenfort et al., 2007; Ramsey et al., 2007).
In tumors from animals with somatic p16
INK4a and/or
p53 inactivation, however, expression of p15
INK4b was
observed in 8 of 12 tumors (Figure 2c). Therefore, any
such compensatory increase in p15
INK4b expression either
does not occur or is insufﬁcient to prevent tumorigenesis
in melanocytes in the setting of somatic deletion of
p16
INK4a. In aggregate, these results imply that acquired
stochastic loss of p16
INK4a, but not of p15
INK4b,i s
commonly associated with in vivo tumor progression in
melanocytes harboring somatic, but not germline, p53
inactivation.
Figure 2 Analysis of INK4–Cdk4/6–Rb and Arf–p53 pathways in representative melanomas. (a) and (b) Western analysis of p16
INK4a
and Arf in tumors of the indicated genotypes. (c) Western analysis of p15
INK4b expression in tumors of the indicated genotypes.
(d) Western analysis of phospho-p53 and Arf in tumors of the indicated genotypes.
p16
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from tumors from mice of informative genotypes.
In accordance with previous reports (Chin et al., 1997;
Bardeesy et al., 2001; Sharpless et al., 2002), we noted
that tumors lacking p53 function almost always
exhibited a markedly increased Arf expression
(Figure 2b and d). As expected, tumors from contem-
poraneously analyzed TyrRas Ink4a/Arf /  mice
showed Arf loss and expression of phosphorylated p53
(Figure 2d). Analysis of TKp16
L/L tumors demonstrated
that four of ﬁve tumors exhibited phospho-p53 expres-
sion (Figure 2d), whereas three of ﬁve tumors exhibited
Arf expression (Figure 2a and d). In particular, at least
two TKp16
L/L tumors (#10 and 11, Figure 2d) exhibited
phospho-p53 and retained Arf expression, consistent
with the possibility of a retained Arf–p53 pathway
function in these tumors. In tumors from 4-OHT-treated
mice that were heterozygous for the ﬂoxed p53 allele,
absent Arf expression was noted in two of ﬁve tumors
(Figure 2b), suggesting that Arf loss can be associated
with tumor progression even in a p53
L/þ background.
Although some TKp16
L/L tumors retained Arf–p53
expression, other TKp16
L/L tumors lost Arf expression,
suggesting that Arf loss can contribute to progression in
some tumors. Overall, these results suggest that somatic
inactivation of the Arf–p53 pathway can occur, but is
not obligate, for progression of K-Ras-induced,
p16
INK4a-deﬁcient melanoma.
In an effort to benchmark these new somatic models
of melanoma to an earlier, well-characterized melanoma
model, we also compared tumors from 4-OHT-treated
TKp16
L/Lp53
L/L mice with contemporaneously analyzed
TyrRas Ink4a/Arf /  mice (Chin et al., 1997). It should
be acknowledged that several relevant biological differ-
ences limit this comparison, including somatic vs germ-
line genetic events; single copy, endogenous K-Ras
mutation vs multicopy, transgenic H-Ras mutation; and
p53 vs Arf loss. Although the tumor-inducing genetic
events occur later (postnatally) in the TKp16
L/Lp53
L/L
model, the tumor latencies were similar between the
somatic and germline models (Figure 3a). Moreover,
when the growth rates of comparably sized tumors were
analyzed in vivo, melanomas from TKp16
L/Lp53
L/L mice
were noted to grow more rapidly with increased
ulceration (Figure 3b). All tumor-bearing TKp16
L/L
p53
L/L mice had to be killed by day 8 of observation
because of advanced tumors, whereas TyrRas Ink4a/
Arf /  mice can routinely be observed for more than 20
days before having to be killed. Cell lines derived from
TKp16
L/Lp53
L/L tumors demonstrated increased S-phase
and aneuploidy compared with TyrRas Ink4a/Arf / 
tumors (Figure 3c, Supplementary Table 1). Consistent
Figure 3 TKp16
L/Lp53
L/L melanomas are more aggressive than those from TyrRas Ink4a/Arf /  mice. (a) Kaplan–Meier analysis of
melanoma-free survival of TKp16
L/Lp53
L/L (n¼15) and TyrRas Ink4a/Arf /  (n¼12) mice (P¼NS). (b) in vivo analysis of tumor
growth of TKp16
L/Lp53
L/L (n¼3) and TyrRas Ink4a/Arf /  (n¼6) tumors. *P¼0.01 at days 6 and 8. (c) in vitro ﬂow cytometry
analysis of the cell cycle in tumor cell lines generated from TKp16
L/Lp53
L/L and TyrRas Ink4a/Arf /  tumors. Increased S-phase and
aneuploidy are noted in tumors from TKp16
L/Lp53
L/L mice (see also Supplementary Table 1). (d) Western analysis of indicated proteins
in lysates from TKp16
L/Lp53
L/L and TyrRas Ink4a/Arf /  tumors.
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increased and p21
CIP levels decreased in TKp16
L/Lp53
L/L
tumors compared with lines from TyrRas Ink4a/Arf / 
tumors (Figure 3d). Further characterization of protein
expression in tumor lysates from the different models
indicated little difference in the expression of tested
downstream mediators of Ras signaling (for example,
phospho-ERK and phospho-AKT, Figure 3d). These
results are consistent with the possibility of a more
aggressive in vivo behavior of TKp16
L/Lp53
L/L tumors as
a result of p53 loss compared with Arf loss in the
TyrRas Ink4a/Arf /  model, although other differences
such as strain background or Ras isoform differences
could also contribute. Importantly, however, despite
technical and biological differences between the models,
they share several common features including tumor
histological appearance, lack of precursor nevus forma-
tion, scant or absent tumor pigmentation and lack of
metastasis. The shared features of Ras-driven, p16
INK4a-
deﬁcient melanoma models are in contrast to the
features of the pigmented, metastatic tumors seen in
B-Raf mutant, Pten-deﬁcient tumors reported by
McMahon and Bosenberg (Dankort et al., 2009).
As epidemiological and murine modeling results have
suggested that ultraviolet B exposure is more oncogenic
at young ages, we studied the in vivo transformability of
somatic K-Ras activation and combined p16
INK4a/p53
loss in adult mice. Toward this end, small (1cm 1cm)
patches of ﬂank skin were topically treated with 4-OHT
in 8-week-old TKp16
L/Lp53
L/L mice and then manually
depilated to stimulate melanocyte proliferation (see Supple-
mentary Figure 1 and Ruzankina et al., 2007). By 15 weeks
post 4-OHT treatment, tumor development was observed
in the majority (17 out of 27) of treated TKp16
L/Lp53
L/L
adult mice (Figure 4a and b), with all tumors developing
at the site of 4-OHT treatment (Figure 4b and c).
The median tumor latency of TKp16
L/Lp53
L/L mice was
modestly longer in animals treated as adults compared
with neonates (Figure 4a), but this may be explained by
the considerably more extensive CRE-mediated recom-
bination observed in neonatally treated mice (not
shown, see also (Bosenberg et al., 2006)). To serially
monitor melanoma development in adult mice, a green
ﬂuorescent protein CRE-reporter allele was crossed into
the TKp16
L/Lp53
L/L model. Through intravital confocal
microscopy of 4-OHT-treated TKp16
L/Lp53
L/L adult
mice, CRE recombination was conﬁrmed in 4-OHT-
treated skin, but not noted in untreated skin (Figure 4c).
Despite a basal level of autoﬂourescence in untreated
skin, all TKp16
L/Lp53
L/LRosa26-LSL-GFPþ tumors
expressed green ﬂuorescent protein, allowing for visua-
lization of individual tumor cells in anesthetized, living
mice. These data are not consistent with the model of a
‘developmental window’ for melanocyte transformabil-
ity, but instead show that adult melanocytes can be
efﬁciently transformed in vivo.
Figure 4 Melanocytes from adult TKp16
L/Lp53
L/L mice are transformable in vivo.( a) Kaplan–Meier analysis of melanoma survival of
4-OHT-treated TKp16
L/Lp53
L/L mice as adults or neonatal pups. Control mice (4-OHT-untreated or lacking the K-Ras-LSL allele
(n¼9)) did not develop tumors. Pairwise comparison of adult-treated (n¼27) vs neonatally treated TKp16
L/Lp53
L/L mice (n¼15)
(P¼0.003). (b) Adult TKp16
L/Lp53
L/L mice developed tumors in depilated and 4-OHT-treated skin patches. 4-OHT-treated control
mice did not develop tumors. (c) Serial intravital confocal imaging of skin from TKp16
L/Lp53
L/LRosa26-LSL-GFPþ mice that were
4-OHT-treated as adults demonstrates green ﬂuorescent protein expression and tumor growth. Melanocytes of untreated skin or of
skin of control mice do not express green ﬂuorescent protein; autoﬂourescence of hair follicles is noted. Original magniﬁcation:  200.
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In this study, we provide evidence that somatic p16
INK4a
deletion and oncogenic K-Ras activation promote the
rapid onset of aggressive melanomas in vivo. To test
somatic loss of p16
INK4a in melanoma, a novel p16
INK4a
conditional allele was generated that exhibits unper-
turbed expression of other Ink4a/Arf locus genes,
p15
INK4b and Arf. We observed potent cooperation
between somatic Ras activation along with somatic
p16
INK4a loss, whereas somatic Ras activation and p53
deletion yield a somewhat more modest melanoma-prone
condition, a ﬁnding consistent the more prominent tumor
suppressor role of p16
INK4a relative to p53 in human
melanoma. These data support the view that conditional
inactivation of p16
INK4a provides a more faithful platform
for the generation of reﬁned mouse models of human
melanoma, and possibly of other cancers.
Moreover, as opposed to work using germline alleles
(Kannan et al., 2003; Sharpless et al., 2003), the use of
these conditional systems provides evidence that direct
Arf-p53 inactivation is not required for in vivo murine
melanoma formation. That is, some tumors arising in
TKp16
L/L mice (Figure 4d) exhibited Arf and phospho-
p53 expression. Although the analysis of TKp16
L/L
tumors suggests that the ARF–p53 pathway retained
expression, this does not eliminate other potential
mechanisms that could abrogate the function of this
pathway, such as point mutations or murine double
minute 2 ampliﬁcation. Nevertheless, although direct
Arf or p53 inactivation does not seem to be an obligate
event for in vivo melanomagenesis, our data and those of
others certainly suggest that either lesion should
strongly enhance tumor progression.
Although the primary tumors of TKp16
L/Lp53
L/L mice
were aggressive in terms of local invasion, we did not
detect metastasis, a hallmark of human melanoma.
Although metastasis has been observed in both an N-
Ras transgenic model that used a multicopy transgene
with a presumed high level Ras activation (Ackermann
et al., 2005) and a somatic B-Raf mutant and Pten
mouse model of melanoma (Dankort et al., 2009),
metastasis has otherwise not been a feature of most
murine melanoma models involving Ras activation, p53
loss and p16
INK4a loss (Chin et al., 1997; Bardeesy et al.,
2001; Sharpless et al., 2003), suggesting that other
factors are involved in metastasis in melanoma. One
potential explanation could relate to Pten status, which
is also inactivated with high frequency in human
melanoma (reviewed in (Chin et al., 2006)). Several
studies have suggested a prominent role for both the
lipid and protein phosphatase activities of PTEN in
regulating cellular motility and invasion (Tamura et al.,
1998; Marino et al., 2002; Raftopoulou et al., 2004; Lin
et al., 2009). Similar to other large tumor suppressor
genes that can be inactivated by a variety of mechan-
isms, studies of PTEN in human cancer have been
limited by difﬁculty in determining whether the gene is
inactivated in a given tumor. Ongoing comprehensive
studies such as the Cancer Genome Atlas involving
multidimensional genome-scale analysis of large clini-
cally annotated samples sets should determine whether
PTEN loss is a primary driver of metastasis in human
melanoma.
In summary, in this paper, we describe a genetically
engineered murine model of melanoma that is based on
somatic Ras activation and p16
INK4a loss, which are
hallmarks of the human disease. This study has shown
that somatic inactivation solely of p16
INK4a, without the
corresponding targeting of Arf, is potently tumorigenic
in vivo. Inactivation of p16
INK4a and p53 with Ras
activation in adult melanocytes was potently oncogenic,
suggesting that adult cells are not substantially less
transformable than neonatal melanocytes. As novel
targeted therapies for the RAS pathway are emerging
for human melanoma (Engelman et al., 2008), these
reﬁned genetic models harboring genetic alterations
encountered in the human disease should enable the
more accurate use of such agents in speciﬁc melanoma
genotypes in the future.
Materials and methods
Mouse colony
Animals were generated and genotyped as previously described
(Johnson et al., 2001; Jonkers et al., 2001; Bosenberg et al.,
2006) and were N1 in C57Bl/6. Mice were housed and treated
in accordance with protocols approved by the institutional
care and use committee for animal research at the University
of North Carolina. Pups were treated for 3 consecutive days
with 4-OHT (Sigma H7904, Sigma, St Louis, MO, USA) at
25mg/ml in dimethyl sulfoxide starting at day 2 (Bosenberg
et al., 2006). Tumor growth and survival were assessed three
times per week by caliper measurements of tumor areas (width
  length (mm
2)) and measurement was taken when tumors
were between 20 and 30mm
2. Tumor growth was normalized
to day 1 values and analyzed using GraphPad Prism software
(GraphPad Software, La Jolla, San Diego CA, USA).
Generation of p16
L/L allele and derivative cells
The p16
INK4a conditional (ﬂoxed) allele (p16
L) was generated
and validated as described in Supplementary Methods. To
evaluate the effects of p16
INK4a excision, 1 10
6 murine embryonic
ﬁbroblasts were treated with CRE-expressing adenovirus (Iowa
Vector Core, Iowa City, IA, USA) at a multiplicity of infection
of 100 for 24h. Cells were split and harvested 5 days after CRE
treatment. To avoid the effects of adenoviral CRE expression
on Arf–p53 expression, we crossed the p16
L/L allele into
lentiviral transgenic CRE-ER
T2 mice (Ruzankina et al., 2007).
Murine embryo ﬁbroblasts containing the CRE-ER
T2 trans-
gene and homozygous for the p16
L/L allele were generated and
cultured on a 3T9 protocol. After four passages, cells were
treated with 10nm 4-OH-tamoxifen (Sigma T5648) for 40h.
After treatment, cell lysates were harvested at passages 1, 3 and
5. Primary melanocyte cultures from mice of the indicated
genotypes, including the TyrCRE-ER
T2 allele, were prepared
as described previously (Bennett et al., 1989; Spanakis et al.,
1992) and plated on collagen-coated dishes. Cells were treated
with or without 4-OHT at 20 days post isolation for 48h.
Successful recombination was conﬁrmed at 22 days and
western blot was performed at 45 days. For growth curve
analysis, cells were counted at indicated times and replated at
3 10
4 cells per ml. The mean relative population increase was
calculated as the number of doublings.
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Tumor cell lines were generated and maintained as described
(Sharpless et al., 2002). For cell cycle analysis, exponentially
growing cells were pulsed for 15min with 10mM bromodeox-
yuridine (BrdU) in Dulbecco’s modiﬁed Eagle’s mediumþ
10% fetal calf serum before harvest. Cells were ﬁxed,
permabilized and stained with anti-BrdU-APC according to
BrdU Flow Kit instructions (BD Pharmingen, San Jose,
CA, USA) and then resuspended in phosphate-buffered
salineþ0.2% fetal calf serumþ25mg/ml propidium iodide
with RNase and analyzed using a CyAn (Dako) ﬂow
cytometer (Cyan ADP, DAKO, Beckman Coulter, Brea, CA,
USA) and FlowJo (Treesoft) software (Treestar, Inc., Ashland,
OR, USA). Experiments were conducted in triplicate.
4-OHT treatment of adult mice and intravital microscopy
Hair on both ﬂanks of 50- to 55-day-old mice was trimmed
(1–2cm
2 section) for treatment. One ﬂank was treated with
20mM 4-OHT dissolved in ethanol (treated skin) and the other
ﬂank was treated with 100% ethanol (control). Treatment was
repeated the next day. Five days after treatment, mice were
anesthetized with 2% isoﬂuorane and depilated by hand
(Ruzankina et al., 2007). For serial confocal imaging of tumors,
mice were anesthetized with ketamine/xylazine and ear fur was
removed using chemical depilation. Green ﬂuorescent protein
ﬂuorescence in the ears was excited with 900-nm light from a
Chameleon Ultra Ti-Sapphire pulsed laser (Coherent, Santa
Clara, CA, USA) and imaged with a Zeiss LSM 510 NLO
inverted 2-photon laser scanning microscope (Thornwood, NY,
USA) using  100.3 NA,  200.5 NA and  401.2 NA (water-
immersion) objectives. Images were captured using a 12-bit cooled
CCD camera (Hamamatsu, Bridgewater, NJ, USA).
Western blots
Western blot assays were performed on tumor lysates in RIPA
buffer with protease inhibitors (Roche, Indianapolis, IN, USA)
and phosphatase inhibitors (Calbiochem, EMD Chemicals
Inc, Darmstadt, Germany) as described (Ramsey et al., 2007).
Antibodies used were p21
CIP (F-8, Santa Cruz, Santa Cruz, CA,
USA), p16
INK4a (M-156, Santa Cruz), b-actin (C-1, Santa Cruz),
cyclin D1 (DCS-6, Cell Signaling, Danvers, MA, USA), cyclin E
(M-20, Santa Cruz), Cdk2 (M2, Santa Cruz), Cdk4 (C-22, Santa
Cruz), p15
INK4b (K18, Santa Cruz), p27
KIP (M20, Santa Cruz),
phospho-p53 (Ser15, Cell Signaling), p53 (CM5, Novocastra
Laboratories Ltd, Newcastle Upon Tyne, UK), p-ERK (9101S,
Cell Signaling), ERK (9102, Cell Signaling), p-AKT (9271S,
Cell Signaling), AKT (9272, Cell Signaling), Bax (Santa Cruz)
and ARF (ab80, Abcam, Cambridge, MA, USA).
Immunohistochemistry
Assistance in sample processing was provided by the University of
North Carolina Center for Gastrointestinal Biology and Disease.
Ears and tumors were ﬁxed in 10% formalin, parafﬁn-embedded,
sectioned, deparafﬁnized and stained using hematoxylin and eosin
for histological analysis. To conﬁrm melanocytic origin, parafﬁn
sections were treated with citrica c i da n ds t a i n e dw i t har a b b i t
anti-TRP1 (gift from Vincent Hearing) at a dilution of 1:500, or
without primary antibody for control samples. Detection was
performed using highly sensitive DAKO EnVision polymerized
horseradish peroxidase. b-galactosidase staining was previously
described (Bosenberg et al., 2006). Samples were analyzed
(Zeiss Axioskop 2) and photographed (Zeiss Axiocam) under
bright-ﬁeld microscopy using  100.25 NA,  200.50 NA
and  401.30 NA objectives.
Statistical analysis
Tumor-free survival was analyzed using GraphPad Prism
software (GraphPad Software) and comparisons were made
using the log-rank test. Tumor sizes were compared using an
unpaired, two-tailed t-test. Error bars±s.e.m.
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